EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
Anixa Biosciences provided an update on its Phase 1 CAR-T clinical trial outcomes for ovarian cancer. The recent regulatory approval for substantial dose escalation may improve therapeutic efficacy, potentially leading to positive outcomes that could drive investor interest.
View signal analysis